Table of contents
Volume 100, Issue 8
Published online 14 April 2009 (1213-1368)
Clinical Studies |
Translational Therapeutics |
Molecular Diagnostics |
Genetics and Genomics |
Letters to the Editor |
Corrigendum
Minireviews
Methodological approaches in application of synthetic lethality screening towards anticancer therapy
D Canaani
Br J Cancer 100: 1213-1218; advance online publication, March 24, 2009; doi:10.1038/sj.bjc.6605000
Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond
R D Riley, W Sauerbrei and D G Altman
Br J Cancer 100: 1219-1229; doi:10.1038/sj.bjc.6604999
Clinical Studies
Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location
L Guittet, V Bouvier, N Mariotte, J P Vallee, R Levillain, J Tichet and G Launoy
Br J Cancer 100: 1230-1235; advance online publication, March 31, 2009; doi:10.1038/sj.bjc.6604996
Preoperative systemic inflammation predicts postoperative infectious complications in patients undergoing curative resection for colorectal cancer
L H Moyes, E F Leitch, R F McKee, J H Anderson, P G Horgan and D C McMillan
Br J Cancer 100: 1236-1239; advance online publication, March 24, 2009; doi:10.1038/sj.bjc.6604997
The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening
I M C M de Kok, J J Polder, J D F Habbema, L-M Berkers, W J Meerding, M Rebolj and M van Ballegooijen
Br J Cancer 100: 1240-1244; doi:10.1038/sj.bjc.6605018
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma
R F Kefford, N P B Thomas, P G Corrie, C Palmer, E Abdi, D Kotasek, J Beith, M Ranson, P Mortimer, A J Watson, G P Margison and M R Middleton
Br J Cancer 100: 1245-1249; advance online publication, March 31, 2009; doi:10.1038/sj.bjc.6605016
O 6-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib
A J Watson, M R Middleton, G McGown, M Thorncroft, M Ranson, P Hersey, G McArthur, I D Davis, D Thomson, J Beith, A Haydon, R Kefford, P Lorigan, P Mortimer, A Sabharwal, O Hayward and G P Margison
Br J Cancer 100: 1250-1256; doi:10.1038/sj.bjc.6605015
Translational Therapeutics
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
D Yoshikawa, H Ojima, A Kokubu, T Ochiya, S Kasai, S Hirohashi and T Shibata
Br J Cancer 100: 1257-1266; advance online publication, March 24, 2009; doi:10.1038/sj.bjc.6604988
Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
P Cao, S-M Maira, C García-Echeverría and D W Hedley
Br J Cancer 100: 1267-1276; advance online publication, March 24, 2009; doi:10.1038/sj.bjc.6604995
The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients
I Van der Auwera, H J Elst, S J Van Laere, H Maes, P Huget, P van Dam, E A Van Marck, P B Vermeulen and L Y Dirix
Br J Cancer 100: 1277-1286; doi:10.1038/sj.bjc.6605013
Intra-tumoural extra-cellular pH: a useful parameter of response to chemotherapy in syngeneic tumour lines
D Lindner and D Raghavan
Br J Cancer 100: 1287-1291; doi:10.1038/sj.bjc.6605022
Molecular Diagnostics
An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET)
H A Rogers, S Miller, J Lowe, M-A Brundler, B Coyle and R G Grundy
Br J Cancer 100: 1292-1302; advance online publication, March 17, 2009; doi:10.1038/sj.bjc.6604979
Differential tissue-specific protein markers of vaginal carcinoma
K Hellman, A A Alaiya, S Becker, M Lomnytska, K Schedvins, W Steinberg, A-C Hellström, S Andersson, U Hellman and G Auer
Br J Cancer 100: 1303-1314; advance online publication, March 24, 2009; doi:10.1038/sj.bjc.6604975
Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts
K Huhtinen, P Suvitie, J Hiissa, J Junnila, J Huvila, H Kujari, M Setälä, P Härkki, J Jalkanen, J Fraser, J Mäkinen, A Auranen, M Poutanen and A Perheentupa
Br J Cancer 100: 1315-1319; advance online publication, March 31, 2009; doi:10.1038/sj.bjc.6605011
BCL6 degradation caused by the interaction with the C-terminus of pro-HB-EGF induces cyclin D2 expression in gastric cancers
Y Hirata, N Ogasawara, M Sasaki, T Mizushima, T Shimura, T Mizoshita, Y Mori, E Kubota, T Wada, S Tanida, H Kataoka, T Kamiya, S Higashiyama and T Joh
Br J Cancer 100: 1320-1329; advance online publication, March 31, 2009; doi:10.1038/sj.bjc.6605010
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
A Oden-Gangloff, F Di Fiore, F Bibeau, A Lamy, G Bougeard, F Charbonnier, F Blanchard, D Tougeron, M Ychou, F Boissière, F Le Pessot, J-C Sabourin, J-J Tuech, P Michel and T Frebourg
Br J Cancer 100: 1330-1335; doi:10.1038/sj.bjc.6605008
DNA copy number loss and allelic imbalance at 2p16 in lung cancer associated with asbestos exposure FREE
E Kettunen, M Aavikko, P Nymark, S Ruosaari, H Wikman, E Vanhala, K Salmenkivi, R Pirinen, A Karjalainen, E Kuosma and S Anttila
Br J Cancer 100: 1336-1342; advance online publication, March 31, 2009; doi:10.1038/sj.bjc.6605012
Genetics and Genomics
Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis
T Pabst, M Eyholzer, J Fos and B U Mueller
Br J Cancer 100: 1343-1346; advance online publication, March 10, 2009; doi:10.1038/sj.bjc.6604977
The BAG-1 cochaperone is a negative regulator of p73-dependent transcription
X-H Wang, D O'Connor, M Brimmell and G Packham
Br J Cancer 100: 1347-1357; advance online publication, March 17, 2009; doi:10.1038/sj.bjc.6604985
Common genetic variability in ESR1 and EGF in relation to endometrial cancer risk and survival
K Einarsdóttir, H Darabi, K Czene, Y Li, Y L Low, Y Q Li, C Bonnard, S Wedrén, E T Liu, P Hall, J Liu and K Humphreys
Br J Cancer 100: 1358-1364; advance online publication, March 24, 2009; doi:10.1038/sj.bjc.6604984
Letters to the Editor
CD133 expression in different stages of gastric adenocarcinoma
M Boegl and C Prinz
Br J Cancer 100: 1365-1366; doi:10.1038/sj.bjc.6605001
Reply: CD133 expression in different stages of gastric adenocarcinoma
L M Smith, A Nesterova, M C Ryan, S Duniho, M Jonas, M Anderson, M K Sutherland, K L Van Orden, P A Moore, S M Ruben and P J Carter
Br J Cancer 100: 1367; advance online publication, March 24, 2009; doi:10.1038/sj.bjc.6605002
Corrigendum
Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy FREE
L Paré, E Marcuello, A Altés, E del Río, L Sedano, J Salazar, A Cortés, A Barnadas and M Baiget
Br J Cancer 100: 1368; doi:10.1038/sj.bjc.6605004
The published online date indicates the date that the issue is published online and is the first official publication date of the issue. Each print issue of BJC is published one week after it has been published online.
